Subham Kumar Vishwakarma

Mr. Subham Kumar Vishwakarma

Biological Sciences, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil
orcid
Doctoral Researcher

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VSVaibhav Singh
Vaibhav Singh
ESEkta Shirbhate
Ekta Shirbhate
RKRakesh Kore
Rakesh Kore
Subham Kumar VishwakarmaSubham Kumar Vishwakarma
Subham Kumar Vishwakarma
SPShadiya Parveen
Shadiya Parveen
HRHarish Rajak
Harish Rajak
Globally, one of the most prevalent cancers is colorectal cancer (CRC). Chemotherapy and surgery are two common conventional CRC therapies that are frequently ineffective and have serious adverse effects. Thus, there is a need for complementary and different therapeutic approaches. The use of microbial metabolites to trigger epigenetic alterations as a way of preventing CRC is one newly emerging field of inquiry. Small chemicals called microbial metabolites, which are made by microbes and capable of altering host cell behaviour, are created. Recent research has demonstrated that these metabolites can lead to epigenetic modifications such as histone modifications, DNA methylation, and non-coding RNA regulation, which can control gene expression and affect cellular behaviour. This review highlights the current knowledge on the epigenetic modification for cancer treatment, immunomodulatory and anti-carcinogenic attributes of microbial metabolites, gut epigenetic targeting system, and the role of dietary fibre and gut microbiota in cancer treatment. It also focuses on short-chain fatty acids, especially butyrates (which are generated by microbes), and their cancer treatment perspective, challenges, and limitations, as well as state-of-the-art research on microbial metabolites-induced epigenetic changes for CRC inhibition. In conclusion, the present work highlights the potential of microbial metabolites-induced epigenetic modifications as a novel therapeutic strategy for CRC suppression and guides future research directions in this dynamic field.

25 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Subham Kumar VishwakarmaSubham Kumar Vishwakarma
Subham Kumar Vishwakarma
Oswaldo Julio RamirezOswaldo Julio Ramirez
Oswaldo Julio Ramirez
Heitor Leocádio de Souza RodriguesHeitor Leocádio de Souza Rodrigues
Heitor Leocádio de Souza Rodrigues
LPLaura Maria Duran Gleriani Primo
Laura Maria Duran Gleriani Primo
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), remains one of the most devastating infectious diseases worldwide, with rising multidrug resistance limiting the effectiveness of conventional treatments. Novel therapeutic approaches are urgently needed to complement or replace existing regimens. Among emerging candidates, antimicrobial peptides (AMPs) stand out as versatile molecules capable of exerting direct antimycobacterial effects while also modulating the host immune response. This review explores peptide-based strategies against TB, with a focus on four major axes of innovation. First, we examine host-directed pathways, including the vitamin D–cathelicidin axis and other immunomodulatory mechanisms and their regulatory role in the induction of endogenous AMPs such as cathelicidin LL-37, which contributes to host-directed defense. Second, we discuss peptide-based vaccines designed to elicit robust and durable protective immunity, representing a complementary alternative to classical vaccine approaches. Third, we highlight the synergistic potential of AMPs in combination with first-line and second-line anti-TB drugs, aiming to restore or enhance bactericidal activity against resistant strains. Finally, we analyze technological platforms, including nanocarriers and inhalable formulations, that enable targeted pulmonary delivery, improve peptide stability, and enhance bioavailability. By integrating molecular design, immune modulation, and advanced delivery systems, peptide-based strategies provide a multifaceted approach to overcoming the limitations of current TB therapy. Collectively, these advances position AMPs not only as promising standalone agents but also as key components in combination and host-directed therapies, with strong potential to reshape the future clinical management of tuberculosis.

13 February 2025 in Journal of Molecular Structure
Verified
Journal Article
Closed access
PNP. Naresh
P. Naresh
MAMahesha
Mahesha
TRT.N. Vinuth Raj
T.N. Vinuth Raj
NSNaveen S.
Naveen S.
MUM.V. Deepa Urs
M.V. Deepa Urs
SRS. Venugopal Rao
S. Venugopal Rao

1 March 2024 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Ekta ShirbhateEkta Shirbhate
Ekta Shirbhate
VSVaibhav Singh
Vaibhav Singh
RKRakesh Kore
Rakesh Kore
Subham Kumar VishwakarmaSubham Kumar Vishwakarma
Subham Kumar Vishwakarma
RVRavichandran Veerasamy
Ravichandran Veerasamy
HRHarish Rajak
Harish Rajak
Scientists are constantly researching and launching potential chemotherapeutic agents as an irreplaceable weapon to fight the battle against cancer. Despite remarkable advancement over the past several decades to wipe out cancer through early diagnosis, proper prevention, and timely treatment, cancer is not ready to give up and leave the battleground. It continuously tries to find some other way to give a tough fight for its survival, either by escaping from the effect of chemotherapeutic drugs or utilising its own chemical messengers like cytokines to ensure resistance. Cytokines play a significant role in cancer cell growth and progression, and the present article highlights their substantial contribution to mechanisms of resistance toward therapeutic drugs. Multiple clinical studies have even described the importance of specific cytokines released from cancer cells as well as stromal cells in conferring resistance. Herein, we discuss the different mechanism behind drug resistance and the crosstalk between tumor development and cytokines release and their contribution to showing resistance towards chemotherapeutics. As a part of this review, different approaches to cytokines profile have been identified and employed to successfully target new evolving mechanisms of resistance and their possible treatment options.

17 March 2026 in RSC Advances
Verified
Journal Article
Open access
PDF file
Subham Kumar VishwakarmaSubham Kumar Vishwakarma
Subham Kumar Vishwakarma
AMAchal Mishra
Achal Mishra
NPNaresh Panigrahi
Naresh Panigrahi
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Hybrid molecules active against Mycobacterium tuberculosis reveal interactions with the essential targets DprE1 and DHFR through structure-based analysis.